Atopic Dermatitis

In this analysis, patterns of global access to biologic drugs for patients with atopic dermatitis were explored among 50 countries.

New PRO data from the INTEGUMENT-1 and –2 studies were presented at the ACAAI 2024 Meeting.

More patients with atopic dermatitis on stapokibart than on placebo achieved ≥ 75% improvement in Eczema Area and Severity Index over 52 weeks.

Many with moderate-to-severe atopic dermatitis do not reach treatment targets in 12 months, underscoring a need for proactive management strategies.

In these data presented at the Fall Clinical Dermatology conference, population-based data on utilization and duration of systemic corticosteroid exposure was highlighted.

These long-term extension trial data from ADORING 3 highlight tapinarof cream’s efficacy in adults and children aged 2 years and older with atopic dermatitis.

These data from the ADapt study, presented at Fall Clinical, suggest improvements among patients with eczema given lebrikizumab-lbkz who had been previously treated with dupilumab.

These data were presented at Fall Clinical, highlighting the reductions in Eczema Area and Severity Index scores and the overall long-term safety profile of tralokinumab-ldrm.

At the Fall Clinical Dermatology conference, Chovatiya presented on chronic hand eczema and facts about its pathophysiology, diagnosis, and management.

The drug’s favorable risk-benefit profile and sustained efficacy through 76 weeks was highlighted in this analysis’s findings.

This overview highlights our upcoming conference coverage at the Fall Clinical Dermatology Conference in Las Vegas.

This analysis reconfirms the efficacy of dupilumab using a single-center design, a large sample size, and patients with chronic hand eczema.

These data suggest more immediate benefits to alitretinoin, though ultraviolet therapy was shown to be cost-effective after 10 years of use.

In this cohort study, the drug survival rates of methotrexate, cyclosporine A, and dupilumab for adolescents with eczema were assessed along with reasons for discontinuation.

In this single center analysis, investigators highlighted results of dupilumab treatment after 3 years among patients with moderate-to-severe eczema.

These data highlight barriers to pediatric treatments for eczema, providing potential strategies for caregivers and patients for adherence improvement.

Medical experts discuss the importance of setting treatment expectations and maintaining dialogue with patients about targets and explain how to decide on a new treatment when switching.

New data reports a notably heightened risk of atopic dermatitis in patients with prurigo nodulais compared with a control cohort.

A new post-hoc analysis has also revealed improvements in quality of life in patients’ caregivers.

An EADV 2024 study suggests dupilumab use during pregnancy is generally safe and may lower risks of preterm labor, gestational hypertension, and diabetes.

Further research is needed to understand the mechanism behind the link as antibiotic exposure is often necessary in care.

Ruxolitinib cream offers an effective nonsteroidal treatment for mild to moderate atopic dermatitis, with proven efficacy and safety for sensitive skin areas.

Medical experts evaluate the role of biologics in atopic dermatitis, including their efficacy and safety, and discuss reasons for switching between systemic treatments.

Medical experts discuss the significance of speed in achieving itch relief when choosing a treatment for atopic dermatitis.

In this interview at EADV, Thaçi was asked to highlight his team’s recent data from the ARCADIA trial program on nemolizumab for patients with eczema.

The 9-month interim results of the TRACE study were presented at EADV 2024, highlighting tralokinumab’s efficacy in a subset of patients with eczema impacting the head and neck areas.

This interview with Alexis features his reaction to the approval of lebrikizumab for eczema and its significance.

The DELTA trial results on delgocitinib cream as a topical option for CHE were presented at the EADV Congress 2024.

Temtokibart showed similar efficacy to dupilumab in treating moderate-to-severe atopic dermatitis, with faster skin hydration improvements in a phase 2a trial.

These new data on treatment of atopic dermatitis and prurigo nodularis were presented by Galderma at the European Academy of Dermatology & Venereology Congress.